tailieunhanh - Báo cáo y học: "Mycophenolate mofetil as maintenance therapy for proliferative lupus nephritis: a long-term observational prospective study"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học General Psychiatry cung cấp cho các bạn kiến thức về ngành y đề tài: Mycophenolate mofetil as maintenance therapy for proliferative lupus nephritis: a long-term observational prospective study. | Laskari et al. Arthritis Research Therapy 2010 12 R208 http content 12 6 R208 RESEARCH ARTICLE Open Access Mycophenolate mofetil as maintenance therapy for proliferative lupus nephritis a long-term observational prospective study 12 1 1 Katerina Laskari Clio P Mavragani Athanasios G Tzioufas Haralampos M Moutsopoulos Abstract Introduction While the role of mycophenolate mofetil MMF in the management of lupus nephritis has been increasingly recognized limited information is available regarding its efficacy and safety as a long-term maintenance treatment. The aim of the present study was to evaluate the efficacy and safety profile of MMF as maintenance therapy for proliferative lupus nephritis. Methods Thirty-three consecutive patients with proliferative lupus nephritis received induction therapy with five to seven monthly intravenous iv pulses of cyclophosphamide CYC plus iv steroids followed by oral MMF 2 g day as maintenance therapy for a median time of 29 months range 9 to 71 months . Primary end points were the achievement of renal remission complete renal remission disease remission - renal and extrarenal - the occurrence of renal relapse chronic renal failure and death. Secondary end points were the extrarenal disease activity and drug adverse events. The clinical and laboratory parameters were compared during follow-up by means of nonparametric statistical tests. Time to event analysis was performed according to the Kaplan-Meier method. Results A significant improvement of all renal parameters was observed at the end of the induction treatment and at the latest follow-up compared to baseline. The rate of patients achieving renal remission until the end of follow-up was 73 whereas that of complete renal remission was 58 . The median survival times in the Kaplan-Meier analyses were 7 and 16 months respectively. Remission was maintained in all but four 12 patients who relapsed within 19 to 39 months after initial response. At the end of .